Rare Gene Mutation Linked to Fatty Liver Disease: New Insights & Potential Treatments

A rare genetic mutation in the MET gene has been identified by Mayo Clinic researchers as a direct cause of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease. This discovery, published in the journal Hepatology, challenges the long-held understanding that MASLD develops primarily from a combination of lifestyle factors and genetic predisposition, suggesting a more direct genetic link in certain cases.

Unraveling the Genetic Roots of Fatty Liver Disease

For years, MASLD – a condition affecting roughly one-third of adults worldwide – has been linked to obesity, type 2 diabetes, and other metabolic conditions. The disease involves an excessive buildup of fat in the liver, potentially leading to inflammation, fibrosis (scarring), cirrhosis, and even liver cancer. The Mayo Clinic explains that MASLD is increasingly recognized as a significant public health concern. Still, the new research highlights that, in some individuals, a single inherited mutation can be the primary driver of the disease.

The breakthrough began with a puzzling case: a father and daughter diagnosed with MASLD who lacked the typical risk factors like diabetes or high cholesterol. This prompted researchers to conduct an extensive genetic analysis, examining over 20,000 genes. Their investigation pinpointed a small alteration within the MET gene, a gene crucial for liver repair and fat processing. When the MET gene doesn’t function correctly, fat accumulates within liver cells, initiating a cascade of inflammation and potential damage.

The Role of the MET Gene and its Impact on Liver Health

The MET gene plays a vital role in several cellular processes, including growth, motility, and morphogenesis. In the liver, it’s particularly important for maintaining the organ’s ability to process fats effectively. The identified mutation disrupts this process, leading to fat buildup and subsequent liver inflammation. As ScienceDaily reports, this disruption can ultimately progress to fibrosis, cirrhosis, and an increased risk of liver cancer.

Researchers collaborated with scientists at the Medical College of Wisconsin to confirm that the mutation interfered with a critical biological process. Genes are composed of DNA sequences that provide instructions for bodily functions. The single altered “letter” within the MET gene’s DNA sequence effectively scrambled the message, preventing the liver from properly metabolizing fat. Notably, this specific genetic variant hadn’t been previously documented in scientific literature or public genetic databases.

Beyond a Single Family: Evidence from Large-Scale Genomic Data

To determine if this MET gene mutation was an isolated incident, the research team analyzed data from Mayo Clinic’s Tapestry study, a large exome sequencing initiative. The Tapestry study has collected germline DNA from over 100,000 participants across the United States, creating a vast genomic database for researching disease-influencing genetic factors.

Among nearly 4,000 adults in the Tapestry study with MASLD, approximately 1% carried rare variants in the MET gene. Crucially, around 18% of these variants occurred in the same key region identified in the original family, strengthening the evidence that this gene plays a significant role in the development of the disease. “This finding could potentially affect hundreds of thousands, if not millions, of people worldwide with or at risk for metabolic dysfunction-associated steatotic liver disease,” stated Dr. Konstantinos Lazaridis, lead author and Executive Director for the Center for Individualized Medicine.

Implications for Diagnosis and Treatment

This discovery underscores the growing importance of precision genomics in clinical care. Mayo Clinic’s Program for Rare and Undiagnosed Diseases has provided comprehensive genomic testing to over 3,200 patients since 2019, aiding in the diagnosis of complex and difficult-to-diagnose conditions, including rare liver diseases. The program collaborates with nearly 300 clinicians across 14 divisions to deliver precision diagnostics.

The identification of the MET gene mutation opens avenues for developing targeted treatments for MASLD. Future research will focus on understanding how this discovery can guide the development of therapies and improve diagnostic approaches. Mayo Clinic Health System highlights the ongoing effort to redefine and raise awareness for steatotic liver disease.

Understanding the Limitations and Future Directions

While this research represents a significant step forward, it’s important to acknowledge its limitations. The study focused on a relatively small number of individuals with the MET gene mutation. Further research is needed to determine the prevalence of this mutation in diverse populations and to fully understand its impact on disease progression. The study also demonstrates correlation, not causation; while the mutation is linked to MASLD, it doesn’t definitively prove it *causes* the disease in all cases. Other genetic and environmental factors likely contribute to the development of MASLD in most individuals.

Researchers are now working to explore how this discovery can be translated into clinical practice. This includes developing more sensitive diagnostic tests to identify individuals with the MET gene mutation and investigating potential therapeutic strategies to correct the gene’s function or mitigate its effects. The Tapestry study will continue to be a valuable resource for identifying other genetic factors that contribute to MASLD and other complex diseases.

What comes next: The Mayo Clinic team plans to expand their genomic studies to include larger and more diverse patient cohorts. They will also investigate the underlying mechanisms by which the MET gene mutation disrupts liver function and explore potential therapeutic interventions. Ongoing surveillance through initiatives like the Tapestry study will be crucial for identifying additional genetic variants and refining our understanding of MASLD.